Motives, may perhaps be preferentially acquired following whole-chromosome loss or the acquisition of structural chromosomal aberrations, at which time increases in oncogene copy numbers may well confer enhanced malignancy. Our observations comparing aneuploidy signatures of early- and late-stage astrocytoma are consistent with this possibility. In any occasion, our analysis expands our expertise in the nature of whole-chromosome aneuploidy in human tumors, supplies some insights into tumor evolution and might eventually be applied for prognostic or therapeutic purposes.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptSupplementary MaterialRefer to Net version on PubMed Central for supplementary material.AcknowledgmentsWe thank Daniel Marks, Juan-Manuel Schvartzman and Rozario I. Thomas for critical reading of the manuscript. This work was supported by a Young Investigator Award from Alex’s Lemonade Stand Foundation (P.H.G.D.), the National Institutes of Overall health (U24CA143840; N.S.) and the Breast Cancer Analysis Foundation (R.B).AbbreviationsaCGH Mb m.s MVA TCGA W-CIN array-based comparative genomic hybridization megabases median survival mosaic variegated aneuploidy The Cancer Genome Atlas whole-chromosome instability
moleculesArticleImidazolyl Ethanamide Pentandioic Acid (IEPA) as Potential Radical Scavenger in the course of Tumor Therapy in Human Hematopoietic Stem CellsLucas C. Pfau, Annegret Glasow, Clemens Seidel and Ina Patties *Department of Radiation Oncology, University of Leipzig, 04103 Leipzig, Germany * Correspondence: ina.Idoxifene Autophagy [email protected]: Pfau, L.C.; Glasow, A.; Seidel, C.; Patties, I. Imidazolyl Ethanamide Pentandioic Acid (IEPA) as Potential Radical Scavenger in the course of Tumor Therapy in Human Hematopoietic Stem Cells. Molecules 2023, 28, 2008. https://doi.org/ ten.3390/molecules28052008 Academic Editor: J annes Reynisson Received: 31 December 2022 Revised: 15 February 2023 Accepted: 16 February 2023 Published: 21 FebruaryAbstract: Radiochemotherapy-associated leuco- or thrombocytopenia can be a frequent complication, e.g., in head and neck cancer (HNSCC) and glioblastoma (GBM) sufferers, usually compromising treatments and outcomes. At the moment, no adequate prophylaxis for hematological toxicities is accessible. The antiviral compound imidazolyl ethanamide pentandioic acid (IEPA) has been shown to induce maturation and differentiation of hematopoietic stem and progenitor cells (HSPCs), resulting in reduced chemotherapy-associated cytopenia. In order for it to be a possible prophylaxis for radiochemotherapy-related hematologic toxicity in cancer individuals, the tumor-protective effects of IEPA must be precluded. In this study, we investigated the combinatorial effects of IEPA with radio- and/or chemotherapy in human HNSCC and GBM tumor cell lines and HSPCs.Glutathione Agarose manufacturer Remedy with IEPA was followed by irradiation (IR) or chemotherapy (ChT; cisplatin, CIS; lomustine, CCNU; temozolomide, TMZ).PMID:24190482 Metabolic activity, apoptosis, proliferation, reactive oxygen species (ROS) induction, long-term survival, differentiation capacity, cytokine release, and DNA double-strand breaks (DSBs) have been measured. In tumor cells, IEPA dose-dependently diminished IR-induced ROS induction but didn’t affect the IR-induced alterations in metabolic activity, proliferation, apoptosis, or cytokine release. Furthermore, IEPA showed no protective impact on the long-term survival of tumor cells following radio- or chemotherapy. In HSPCs, IEPA alone slightly enhanced CFU-.
